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Objectives This study sought to evaluate the in vivo magnetic resonance imaging (MRI) efficacy of manganese [Mn(II)] mo-
lecular imaging probes targeted to oxidation-specific epitopes (OSE).
Background OSE are critical in the initiation, progression, and destabilization of atherosclerotic plaques. Gadolinium [Gd(III)]-
based MRI agents can be associated with systemic toxicity. Mn is an endogenous, biocompatible, paramagnetic
metal ion that has poor MR efficacy when chelated, but strong efficacy when released within cells.
Methods Multimodal Mn micelles were generated to contain rhodamine for confocal microscopy and conjugated with ei-
ther the murine monoclonal IgG antibody MDA2 targeted to malondialdehyde (MDA)-lysine epitopes or the hu-
man single-chain Fv antibody fragment IK17 targeted to MDA-like epitopes (“targeted micelles”). Micelle formu-
lations were characterized in vitro and in vivo, and their MR efficacy (9.4-T) evaluated in apolipoprotein-deficient
(apoE/) and low-density lipoprotein receptor negative (LDLR/) mice (0.05 mmol Mn/kg dose) (total of 120
mice for all experiments). In vivo competitive inhibition studies were performed to evaluate target specificity.
Untargeted, MDA2-Gd, and IK17-Gd micelles (0.075 mmol Gd/kg) were included as controls.
Results In vitro studies demonstrated that targeted Mn micelles accumulate in macrophages when pre-exposed to MDA-
LDL with 10 increase in longitudinal relativity. Following intravenous injection, strong MR signal enhance-
ment was observed 48 to 72 h after administration of targeted Mn micelles, with colocalization within intra-
plaque macrophages. Co-injection of free MDA2 with the MDA2-Mn micelles resulted in full suppression of MR
signal in the arterial wall, confirming target specificity. Similar MR efficacy was noted in apoE/ and LDLR/
mice with aortic atherosclerosis. No significant differences in MR efficacy were noted between targeted Mn and
Gd micelles.
Conclusions This study demonstrates that biocompatible multimodal Mn-based molecular imaging probes detect OSE within
atherosclerotic plaques and may facilitate clinical translation of noninvasive imaging of human atherosclerosis.
(J Am Coll Cardiol 2012;59:616–26) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.10.881Oxidized low-density lipoproteins (OxLDL) have been iden-
tified as one of the main factors in the initiation, progression,
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February 7, 2012:616–26 Imaging of Ox-Specific Epitopes Using Mn Probeswall initiates the recruitment and activation of monocytes,
thereby promoting macrophage accumulation. Once activated,
intraplaque macrophages take up OxLDL in an unregulated
fashion, forming foam cells that are retained in the arterial wall.
Apoptosis and necrosis of foam cells amplifies chronic inflam-
matory responses and eventually leads to plaque rupture.
Since OxLDL is immunogenic, murine and human
monoclonal antibodies that bind unique OSE can be gener-
ated and have been identified, characterized, and purified and
shown to bind to murine and human atherosclerotic plaques.
Recently, we have reported the use of oxidation-specific anti-
body (MDA2, E06, and IK17)-labeled gadolinium (Gd)
micelles and iron oxide nanoparticles for the in vivo detection
of OSE in atherosclerotic lesions of apoE/ mice using
magnetic resonance imaging (MRI) (5,6) and showed that
these nanoparticles accumulate within intraplaque macro-
phages. In vitro cell studies strongly suggested that uptake is
specific and receptor mediated, and relies upon interaction
of the targeted nanoparticle with endogenous OxLDL.
Once taken up by macrophages, the entire lipid nanoparticle
is metabolized within intracellular vesicles (lysosomes/
endosomes). Although chelated Gd is renally excreted
(99.9%) bioretention and in vivo biotransformation of
Gd(III) micelles was observed due to their prolonged
half-life. This may lead to systemic toxicity in renally
impaired patients (7–9).
Manganese (Mn(II)) is an endogenous paramagnetic
metal that has been used in other Food and Drug
Administration-approved contrast agents for hepatocyte
targeting and MR liver indications (10,11). Although bio-
compatible, Mn is typically not used in MR contrast agent
development due to its low magnetic moment that limits
MR signal enhancement relative to Gd. However, studies
have indicated that if Mn is delivered into a cell, interaction
with intracellular components and metalloproteinase results
in significant (20-fold) increases in MR efficacy (Fig. 1)
(12–14). On the basis of prior studies with targeted Gd
Figure 1 Diagram of the Efficacy of OSE
Targeted Mn Micelles in the Vascular Phase
Mn is chelated to DTPA. Mn is released with the endosomes/lysosomes after
uptake into intraplaque macrophage/foam cells (black circle). Due to intracel-
lular release of Mn and subsequent interaction with intracellular components,
the magnetic resonance (MR) signal is greatly enhanced. The r1 values are
derived from Table 2. OSE  oxidation-specific epitope.smicelles, we hypothesized that it
may be possible to produce Mn
probes that exhibit limited MR
efficacy in the vascular phase in
which the Mn remains com-
pletely chelated but high MR
efficacy once Mn is released
within intraplaque macrophages
and foam cells. The intracellular
release of Mn would enhance the
MR signal by increasing the
number of water exchange sites
(q  0) and by decreasing the
molecular tumbling rates due to
interaction with macromolecules
and cell membranes. Chelation
in the vascular phase has 2 sig-
nificant effects: 1) it reduces po-
tential cardiotoxicity associated
with bolus injection of free Mn (MnCl2); and 2) back-
round signal from blood is nominal since there are no inner
phere water exchange sites available (q  0) if diethylene-
riamine pentaacetic acid (DTPA) is used as the chelating
gent. The antibody associated with the surface of the
article allows for binding of the micelle to endogenous
SE found in circulation and/or within the arterial wall
5,6). The Mn micelle-Ab-OxLDL complex is then taken
p by intraplaque foam cells/macrophages, as shown with
d micelles. This degradation would result in the intracel-
ular release of the Mn metal ions that are then either taken
p by metalloproteinase or interact with the cell membrane.
The aim of the current study was, therefore, to synthe-
ize, characterize, and evaluate the MR efficacy of targeted
n molecular imaging probes to OSE in murine models of
therosclerosis and to compare their imaging properties
ith previously described Gd targeted probes (5).
aterials and Methods
ntibodies and micelle synthesis. MDA2 is a murine
mmunoglobulin G (IgG) monoclonal antibody that
inds malondialdehyde (MDA)-lysine epitopes present
n OxLDL (15,16). IK17 is a human single-chain Fv
ragment that recognizes an MDA-related epitope ex-
ressed on both MDA-LDL and copper-oxidized LDL.
he following micelle formulations were prepared: untar-
eted Mn and Gd micelles, MDA2-Mn and Gd micelles,
nd single-chain Fv fragment IK17-Mn micelles.
haracterization. All micelle formulations were character-
zed with respect to particle size, zeta potential, Mn or Gd
ontent, in vitro MR efficacy, vascular stability, and uptake
y J447A.1 murine macrophages. Relaxometry was used to
valuate transmetallation of the Mn and Gd from untar-
eted formulations to other proteins in human plasma.
nimal models. All mice used in the current study are
Abbreviations
and Acronyms
%ID  percent injected
dose(s)
%NENH  percent
normalized enhancement
ICP-MS  inductively
coupled plasma mass
spectroscopy
MR  magnetic resonance
MRI  magnetic resonance
imaging
OSE  oxidation-specific
epitope(s)
OxLDL  oxidized low-
density lipoprotein(s)
SI  signal intensityummarized in Table 1.
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Imaging of Ox-Specific Epitopes Using Mn Probes February 7, 2012:616–26Neurotoxicity. Since studies have shown that high repeat
intravenous administration of MnCl2 may lead to neuro-
oxicity, the uptake of the polyethylene glycol (PEG)
icelles was evaluated in murine models of Alzheimer’s
isease (17). This model was chosen because studies have
hown significant OSE deposition in the lesions of these
ice (18). Due to the high endogenous concentration of
n, dysprosium (Dy) micelles were prepared as described in
he previous text for Mn and Gd micelles. The DyDTPA-
is(stearyl-amid) was provided by Avanti Polar Lipids,
labaster, Alabama). It should be noted that due to the high
lectronic relaxation rate and susceptibility of Dy, uptake of
y into tissue results in MR signal loss (19). Mice were
njected with 0.075 mmol Dy/kg of either untargeted (n 
) or MDA2-labeled (n  3) Dy micelles. MRI was
erformed prior to injection and over a 72-h time interval
ost-injection. Immediately following the last scan, mice
ere sacrificed, saline perfused, and the brain excised,
leaned, and weighed. The concentration of Dy (per gram
et weight) was then determined using inductively coupled
lasma mass spectroscopy (ICP-MS).
n vivo MRI. All in vivo MRI was performed at 9.4-T
400 MHz, Bruker Instruments, Billerica, Massachusetts),
sing previously reported methodology (5,6). In short, all
nimals underwent a pre-injection MR scan within 24 h
rior to the administration of the various micelle formula-
ions. MRI was performed over a 1-week time interval after
ail vein injection of either a 0.050 mmol Mn/kg dose or a
.075 mmol Gd/kg dose of micelles. MRI of the abdominal
orta was performed using a T1-weighted black blood
pin-echo sequence (TR/TE/flip  800 ms/8.6 ms/30°,
umber of excitations  16, field of view  2.6 cm  2.6
m) with a microscale in-plane resolution of 0.098 mm2. In
rder to quantitatively evaluate the MR data, signal inten-
ity (SI) measurements were obtained using regions of
nterest within the aortic wall on slices (n  3) exhibiting
signal modulation post-contrast using ImageJ software (Na-
tional Institutes of Health, Bethesda, Maryland). SI mea-
surements of adjacent muscle and the standard deviation
Overview of All In Vivo StudiesTable 1 Overview of All In Vivo Studies
Study Description
pKa Blood drawn over a 24-h time period in n  3/formulation
Untargeted, MDA2, and IK17 Mn(II) formulations tested
Biodistribution Tissue excised after 24 h, 48 h, 72 h, 96 h, and 1-week in
Untargeted, MDA2, and IK17 Mn(II) formulations tested.
Neurotoxicity MRI and brain uptake of targeted and MDA2 micelles (n 
MRI in apoE/ mice MRI performed over a 1-week time interval post-injection (
Untargeted, MDA2, and IK17 Mn(II) formulations tested. M
Competitive inhibition MRI performed over a 1-week time interval post-injection (
Only MDA2 Mn(II) formulation tested.
MRI in LDLR/ mice MRI performed over a 1-week time interval post-injection (
Only untargeted and MDA2 Mn(II) formulations tested.
Values are n.
MR  magnetic resonance; WT  wild type.associated with noise were also obtained for each slice. The spercent normalized enhancement (%NENH), relative to
muscle, was then determined for the aortic vessel wall and
liver according to established methods (5). The %NENH
values reflect the percent relative change in the contrast-to-
noise ratios as a function of time post-injection. For
neuroimaging, T2-weighted spin-echo sequences were used
(TR/TE  125 ms/18 ms, number of excitations  8, field
f view  2.6 cm  2.6 cm, 12 slices). The anatomy of the
brain was used to match the images pre- and post-injection.
The SI measurements were obtained using regions of
interest within the cerebellum, cerebrum, and locations
exhibiting lesion deposition (slices: n  2). The %NENH,
relative to muscle, was then determined.
Confocal microscopy. To evaluate J774A.1 macrophage
uptake or colocalization of the rhodamine-labeled micelles
within the arterial wall, confocal microscopy was performed
as reported previously (5).
In vivo competitive inhibition studies. The specificity of
the MDA2-Mn micelles for MDA-lysine epitopes within
the vessel wall of apoE/ mice was evaluated using in vivo
competitive inhibition, as previously described (5,6).
Immunohistochemistry. MDA epitopes detected using
purified guinea pig antiserum MDA3 (1:500 dilution), as
described previously (6,15).
The study materials and methods are described in greater
detail in the Online Appendix.
Results
Physical properties, relaxivities, and half-life of the various
micelle formulations. The micelle formulations were 10 to
22 nm in size (Table 2), similar to other PEG-DSPE–
based micelles (5,20). The smaller hydrated particle size
observed for Mn micelles relative to Gd was likely due to
limited water coordination associated with the q  0 Mn
ormulations. The addition of the antibodies resulted in an
ncrease in the mean hydrated particle size of all formula-
ions tested. Due to the higher magnetic moment, as well as
he ability to coordinate water protons within the inner
apoE/ Mice LDLR/ Mice WT Mice
9 9
. n  3 formulation/time point. 45
mulation) 6
/formulation). 32
d (III) micelles retested.
/formulation). 3
/formulation). 16.
jection
3/for
n  8
DA2 G
n  3
n  8phere (q 1 for GdDTPA), all Gd formulations exhibited
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February 7, 2012:616–26 Imaging of Ox-Specific Epitopes Using Mn Probessignificantly greater r1 values in HEPES buffer relative to
equivalent Mn micelles (21). The r1 values observed for the
Mn micelles were, however, higher than those expected for
q  0 complexes (21). The elevated r1 values are likely
caused by an added second sphere contribution due to the
presence of uncoordinated carboxylic groups. All antibody-
labeled micelles exhibited increased r1 values when analyzed
in apoE/ mouse blood, relative to values measured in
ild-type mouse blood (Table 2). The intracellular r1 values
btained for MDA2-Mn micelles (45.5  5 s1nM1),
which were pre-incubated with MDA-LDL in J744A.1
macrophages, were significantly greater than the values
obtained in either HEPES buffer (4.1  0.2 s1nM1) or
apoE/ mouse blood (8.1  0.4 s1nM1). No significant
intracellular r1 values were observed for untargeted Mn
micelles, thereby suggesting limited intracellular uptake of
the untargeted formulation. The surface charge, as defined
by the zeta potential, was significantly greater for Gd versus
micelles (6  1 mV vs. 4  1 mV, p  0.01).
Vascular stability. Untargeted Gd micelles show no sig-
nificant change in the r1 values after 24-h incubation but
did show an initial increase in the r1 values in plasma (time
5 min) relative to buffer (r1  14 vs. 10.4 s1mM1, p 
0.01). This may be indicative of an initial and potentially
rapid transmetallation that occurs within 5 min post-
incubation. For the untargeted Mn micelles, the r1 values
decreased by 6% over the 24-h time period studied (3.75 vs.
3.50 s1mM1). The initial r1 values in plasma were not
ignificantly different than those observed in buffer, indicat-
ng slower kinetics of the transmetallation relative to Gd.
The IK17-Gd and IK17-Mn micelles exhibited 3.5% and
.5% transmetallation after incubation with 20 mol/l zinc
nd copper, respectively, suggesting that both the Gd and
n formulations are susceptible to in vivo transmetallation
ith endogenous metal ions (Fig. 2).
acrophage uptake of antibody-micelle formulations.
ignificant cell association (binding and/or uptake) of
K17-Mn by J774A.1 macrophages pre-exposed to MDA-
DL was noted (Fig. 3). Only limited unspecific uptake was
bserved for the untargeted micelles. These results are
Physical Properties, Relaxivities and Half-Life of the Various MicellTable 2 Physical Properties, Relaxivities and Half-Life of the Va
Formulation
Size <d>n
(nm)
Buffer
(s1mM1)
W
(s
Untargeted Mn(II) 10 2 4.1 0.2 3
Untargeted Gd(III) 14 2 11.6 0.3 10
MDA2-labeled Mn(II) 18 3 4.1 0.2 3
MDA2-labeled Gd(III) 22 2 9.8 0.3 10
IK17-Mn 12 2 3.8 0.2 3
IK17-Gd 16 3 10.5 0.3 10
Values are mean  SD. dn is the hydrated particle diameter (number weighting). The longitu
poE/mouse blood. Blood half-lives (t1/2) were obtained in apoE/mice following administra
observed. †Significant (p  0.01) difference in the r1 values observed in WT mouse blood versus
DL  detectable limit.onsistent with previously reported results that show specificptake of OxLDL-targeted Gd micelles by in vitro macro-
hages (6).
harmacokinetics and biodistribution. Targeted (with
oth MDA2 and IK17) Mn and Gd micelles had significantly
onger (5 to 10) circulating half-lives than untargeted mi-
elles in apoE/mice (Table 2). The endogenous background
concentration of Mn in apoE/mouse blood was 0.32 0.05
g/ml. Multiexponential decay was observed for all Mn
formulations, thereby suggesting recirculation of metabolized
Mn. Additionally, the variation observed in the pKa between
the Mn and Gd micelles is likely due to differences in dose or
number of particles injected (0.05 mmol Mn/kg and 0.075
mmol Gd/kg), as well as differences in surface charge (zeta
potential) associated with the particles (4 mV for Mn
icelles and 6 mV for Gd micelles).
The biodistribution of untargeted and MDA2-Mn mi-
elles in the liver, kidney, and aorta are shown in Figure 4.
ompared with MDA2-Gd micelles, significantly higher
Micelles
r1, 60 MHz
t1/2h
d
1)
apoE/ Blood
(s1mM1)
J744A.1 Intracellular
(s1mM1)
.4 4.2 0.3 DL 3.4*
.4 10.8 0.4 — 1.5
.3 8.1 0.4† 45 5 16.4*
.2 12.6 0.2† — 14.3
.4 8.2 0.4† — 12.3*
.3 12.6 0.3† — —
laxivities (r1) were determined at 60 MHz and 40° C in buffer, wild-type mouse blood (WT), and
.05 mmol/kg or 0.075mmol/kg Mn(II) and Gd(III) micelles, respectively. *Multiexponential decay
/ mouse blood.
Figure 2 Percent Transmetallation of IK17-Labeled Mn(II) and
Gd(III) Micelles After Exposure to Copper and Zinc
All samples were prepared in 2% bovine serum albumin, and the percent trans-
metallation determined using relaxometry methods. *p  0.05, #p  0.01 rep-
resents Mann-Whitney test for differences between groups at each condition.esrious
T Bloo
1mM
.9 0
.5 0
.9 0
.6 0
.6 0
.6 0
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observed within the aorta, and significantly lower uptake in
the liver 24 h post-injection. Untargeted micelles exhibited
limited uptake in the arterial wall. Whereas the excretion
kinetics of MDA2-Gd out of the arterial wall was complex,
the elimination of MDA2-Mn micelles was mono-
exponential with an elimination half-life of 58.7 h, and all
Mn was eliminated from the kidneys within 168 h post-
injection. Residual kidney uptake (0.97% injected dose
[%ID]) was observed for the MDA2-Gd micelles at 1 week
post-injection. No significant uptake (0.05%) of untar-
geted or MDA2-Mn micelles was observed in the following
tissue at any of the time points tested: lung, bone, and heart.
At 24 h post-injection, approximately 0.1% of the MDA2-
labeled Mn(II) formulation was present within the spleen.
MDA2-Gd micelles, however, exhibited significant uptake
in the lung (0.47% ID), heart (0.35% ID), bone (0.17% ID),
and spleen (6.27% ID) at 48 h post-injection.
The initial lower uptake of Mn micelles within the liver,
spleen, and kidney is likely a function of dose (lower concen-
tration of Mn micelles injected relative to Gd micelles).
However, the higher uptake of targeted Mn micelles within
the arterial wall may be related to charges that may influence
the binding of the targeted particles to endogenous OSE.
Variations in the excretion kinetics, however, are likely related
to the rate of intracellular metabolism of Mn and Gd.
Neurotoxicity. No significant (p 0.1) change in the MR SI
as observed in the brain of Alzheimer’s mice after adminis-
ration of either untargeted or targeted micelles. Additionally,
ll ex vivo Dy tissue concentrations determined by ICP-MS
ere below method detection limits. As a result, the Dy
Figure 3 Confocal Imaging of Activated J774A.1 Macrophages
Images of the macrophages were made 24 h after incubation with untargeted and
All cell nuclei were DAPI labeled (blue), and all micelles were rhodamine labeled (oncentration within the brain could not be accurately deter-ined. On the basis of these findings, it is evident that the
EG micelles are unable to cross the intact blood-brain barrier.
n vivo MRI. Serial imaging was performed at baseline
nd at 24, 48, 72, and 96 h and 1 week post-injection of
argeted micelles. Significant and robust MR signal en-
ancement was observed in the arterial wall of apoE/
mice following administration of a 0.05 mmol Mn/kg dose
of MDA2-Mn and IK17-Mn micelles (Fig. 5), relative to
untargeted formulations. Maximum signal enhancement
was observed 48 to 72 h after administration of the
OSE-targeted Mn micelles. Quantitatively, MDA2 and
IK17-Mn micelles exhibited 141  20% and 125  6%,
espectively (p  0.001 for each compared with pre-
njection values) higher signal than adjacent muscle at 48 h
ost-injection. Additionally, MR signal enhancement of
24  7% was observed in LDLR/ mice 48 h after
dministration of MDA2-Mn micelles (Fig. 6). Although
he mean values were lower in LDLR/ mice, no statisti-
cally significant difference was observed between the
apoE/ and LDLR/ mice. In vivo competitive inhibi-
tion studies in apoE/ mice showed a 92% (p  0.001)
reduction in MR signal for mice administered free MDA2
at the time of MDA2-Mn micelle injection.
MRI of the MDA2-Gd micelles showed maximum
signal occurring (%NENH  156  21%) at 1 week after
he administration of a 0.075 mmol Gd/kg dose (Fig. 7).
he results obtained in the current study were similar to
hose reported for 12- to 13-month-old apoE/ mice
following administration of MDA2-Gd micelles (5). No
significant difference in the MR efficacy was observed
labeled Mn(II) and Gd(III) micelles.IK17-
red).between the MDA2-Mn and MDA2-Gd micelles at the
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February 7, 2012:616–26 Imaging of Ox-Specific Epitopes Using Mn Probesoptimal imaging time points post-injection (48 h vs. 1 week,
respectively).
Plaque macrophage uptake of targeted micelles. Confo-
cal microscopy confirmed the uptake of MDA2-Mn mi-
celles within atherosclerotic lesions and specifically within
intraplaque foam cells 48 h post-injection (Fig. 8).
Rhodamine-labeled targeted micelles were not observed in
the extracellular matrix. Additionally, rhodamine was not
present within the arterial wall after 1 week post-injection.
These results are consistent with the findings reported for
MDA2-Gd micelles (5). For the untargeted Mn micelles,
no significant rhodamine signal was observed within the
arterial wall at any of the time points tested. MDA epitopes
were present in regions exhibiting plaque deposition and
Figure 4 Biodistribution of Untargeted Mn(II) Micelles,
MDA2-Labeled Mn(II) Micelles, and Gd(III) Micelles
Biodistribution is shown for the liver (A), kidney (B), and aorta (C) of apoE/
mice. Dosages of 0.05 mmol/kg and 0.075 mmol/kg Mn(II) and Gd(III) were
administered, respectively. The percent injected doses (%ID) were determined
based upon the wet weight of the tissue. Kruskal-Wallis test was used to
assess differences between the 3 types of micelles. *p  0.05 comparing
MDA2-Mn and MDA2-Gd micelles. #p  0.05 comparing untargeted and MDA2-
labeled Mn(II) formulations. p.i.  post-injection.signal enhancement by MRI (Fig. 9), consistent with ohistological findings from prior radionuclide imaging stud-
ies using the same targeting antibodies (15,16).
Discussion
This study demonstrates the novel development of Mn-
based MR molecular imaging probes and their successful
application of serial, noninvasive imaging of atherosclerotic
plaques in 2 murine models of atherosclerosis. These mul-
timodal micelles are composed of an optical tag, the Mn for
MRI, and oxidation-specific antibodies to enhance specific
targeting of atherosclerotic lesions. Importantly, although
MnDTPA-based probes theoretically exhibit less MR effi-
cacy than equivalent GdDTPA probes, these specifically
designed Mn probes accumulated within intraplaque
macrophages, presumably due to binding of extracellular
OxLDL in the vessel wall or plasma, and subsequent uptake
in macrophages through scavenger receptors. The intracel-
lular accumulation of targeted Mn micelles and demetalla-
tion resulting in free Mn, noted both in vitro and in vivo,
resulted in significant increases in intracellular r1 values,
enhanced MR efficacy, and effective imaging of atheroscle-
rotic lesions. Furthermore, specific targeting of OSE was
demonstrated by the fact that untargeted control micelles
provided limited lesion enhancement and that cotreatment
of animals with free MDA2 and MDA2-Mn micelles
showing markedly reduced MR signal enhancement due to
blocking of available antibody binding sites. Since Mn is a
relatively nontoxic cation, and noncardiovascular formula-
tions are FDA approved, these data provide a framework for
the clinical translation of this approach to imaging human
atherosclerosis and vulnerable plaques.
Mn is a paramagnetic endogenous metal ion that is
considered safe when chelated during the bolus injection
(22,23). Chelation of Mn during the bolus is critical in order
to eliminate cardiotoxicity caused by the competition of Mn
ions with calcium in normal cardiomyocytes. However,
studies have shown that even soluble Mn (as MnCl2) is safe
f it is administered as a slow infusion (24). In the current
tudy, DTPA was used to chelate Mn in the vascular phase.
lthough limited vascular transmetallation was observed,
he kinetics associated with the vascular release of Mn was
elatively slow (5 min). These findings are consistent with
eported MnDTPA-BMA data that show relatively slow
inetics with transmetallation half-lives in human plasma of
2 min (non–first-order kinetics) (25). Reported studies
sing similar GdDTPA lipid micelle constructs have shown
.6% transmetallation of Gd 3 h after injection in mice (26).
lthough minor vascular transmetallation is observed with
he Mn micelle formulations, toxicity issues caused by the
iotransformation and bioretention of Mn chelates are
inimal compared with that of equivalent Gd formulations
7,27). Additionally, since the PEG micelles are unable to
ross the intact blood-brain barrier, issues related to neuro-
oxicity are expected to be nominal. The small concentration
f Mn that may transmetallate in the vascular phase is also
622 Briley-Saebo et al. JACC Vol. 59, No. 6, 2012
Imaging of Ox-Specific Epitopes Using Mn Probes February 7, 2012:616–26not expected to induce neurotoxicity. Reported toxicity
studies using FDA-approved MnDPDP (Teslascan [man-
gafodipir trisodium], General Electric, Princeton, New
Jersey) that undergoes 20% transmetallation in the vascular
phase does not induce clinical signs indicative of neurotox-
icity (28).
Studies have shown that most cells quickly metabolize or
utilize soluble Mn either via integration into Mn-specific
metalloproteins or interaction with other cellular compo-
nents such as the cell membrane (12,13). The in vivo
biodistribution data showed 97% clearance of the
MDA2-Mn micelles within 1 week post-injection. The
MDA2-Gd micelles, however, exhibited only 72.9% clear-
ance within 1 week post-injection. The variation in the
retention is due to differences in the rate of metabolism of
Mn and Gd micelles. For example, confocal studies show
that the targeted PEG micelles were completely degraded
within intraplaque macrophages 72 h after injection (rho-
Figure 5 Representative MR Images of the Abdominal Aorta of
Images of the abdominal aorta (white arrows) were made after a dose of 0.05 m
(%NENH) values represent the relative change in the contrast-to-noise ratios pre- a
MDA2 antibody was co-injected with the MDA2-labeled Mn micelles to compare th
ences between groups compared with the untargeted (Untar.) Mn micelles. MR damine signal is no longer present). However, as confirmedby ICP-MS as well as MR imaging, Gd is still present
within the arterial wall. These data illustrate that the
targeted micelles and Gd or Mn label track together at early
time points post-injection (72 h). However, as the intra-
plaque macrophages internalize and degrade the particles,
the lipids forming the micelles and MR label are no longer
colocalized within the arterial wall. During intracellular
metabolism, the cells degrade the particles, and the MR
label is released from the chelate. For targeted Mn micelles,
the Mn interacts with cellular components and eventually is
either exocytosed or integrated into the endogenous Mn
pool. However, demetallation of Gd results in the formation
of insoluble Gd salts that remains within the intracellular
vesicles (8). So, whereas the half-life of Mn within the
arterial wall was approximately 60 h (or 2.5 days),
MDA2-Gd micelles exhibit prolonged retention of Gd (1
week).
The results of the current study strongly indicate that the
/ Mice Following Injection of Mn Micelles
n/kg Mn of micelles were injected. The percent normalized enhancement
st-imaging. For the competitive inhibition (Compt. Inh.) studies, 3 mg of free
es of micelles. *p  0.05, #p  0.01 represents Kruskal-Wallis tests for differ-
tic resonance; p.i.  post-injection; Pre  pre-injection.apoE
mol M
nd po
e 4 typ
magnenovel Mn probes allow for specific delivery of Mn to the
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several lines of evidence. 1) The strong MR signal enhance-
ment observed within the arterial wall 48 to 72 h post-
injection of MDA2- or IK17-Mn micelles. Strong signal
enhancement may only be observed after intracellular
demetallation of Mn. 2) Consistent with specific targeting
mechanisms, pre-injection with free MDA2 resulted in
complete MR signal inhibition of MDA2-Mn micelles. If
passive unspecific uptake mechanisms were present, then
the addition of excess free MDA2 would not limit uptake
into intraplaque macrophages, and the MR signal would not
be affected. 3) Confocal microscopy confirmed uptake of the
micelles within intraplaque macrophages and the presence
of MDA epitopes. 4) The fact that the MR signal and
rhodamine signal returned to baseline within 1 week post-
injection is indicative that the intraplaque macrophages/
foam cells are able to effectively degrade and clear the
demetallated Mn and lipid fragments within a relatively
short time period post-injection. The molecular mecha-
nisms through which targeted micelles accumulate in mac-
rophages after being exposed to OxLDL are actively being
investigated and may be mediated through macrophage
scavenger receptors, macropinocytosis, or other mecha-
nisms. Future studies are underway to fully define the
Figure 6
Representative MRI of apoE/ and LDLR/ Mice
48 and 72 h After Administration of
MDA2-Labeled Mn Micelles
No significant differences were noted between groups using the Mann-Whitney test.
MR  magnetic resonance. Abbreviations as in Figure 5.mechanism of intracellular uptake.This study significantly advances the approach of target-
ing OSE for molecular imaging of atherosclerotic lesions
noninvasively by providing both a more easily translatable
approach and higher specificity for targeting OxLDL-
enriched macrophages. Prior studies using radiolabeled
oxidation-specific antibodies have shown that their uptake
in mouse and rabbit atherosclerotic lesions is strongly
correlated with plaque burden, measured both as percent
atherosclerosis surface area and aortic weight (15,16,29).
Furthermore, in dietary regression studies, it was demon-
strated that reduced plaque uptake of radiolabeled antibod-
ies was highly sensitive to regression of atherosclerosis and
removal of OSE (29). In fact, areas within the aorta where
the loss of OSE was greatest were characterized by pheno-
types of plaque stabilization, such as absence of OxLDL and
macrophages, and accumulation of smooth muscle cells
and collagen. Furthermore, in rabbits with very advanced
plaques containing fibrous lesions, there was also evi-
dence of reduced OxLDL content and antibody accumu-
lation. If these results can be confirmed in patients, one
would be able to quantitate the burden of OSE and
monitor their regression.
We have recently reported that targeted Gd micelles may
be used to accurately identify OSE within the arterial wall of
apoE/ mice using high-resolution MR imaging (5). We
have validated and significantly extended these observations
by performing comparative studies of transmetallation, se-
rial pharmacokinetics, biodistribution, and imaging to 1
week with both Gd and Mn IK17 micelles and MDA2
micelles in age-matched LDLR/ and apoE/ mice.
Although MDA2-Mn micelles were administered at a dose
Figure 7 Comparison of MDA2-Labeled
Gd and Mn Micelles in apoE/ Mice
Mice were administered 0.075 mmol/kg and 0.05 mmol/kg Gd and Mn,
respectively. *p  0.05, #p  0.01 represents Mann-Whitney test for differ-
ences between groups at each time point. Abbreviations as in Figure 5.
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enhancement was observed at the optimal imaging time
points post-injection. For targeted Mn micelles, maximum
signal enhancement was observed 48 to 72 h post-injection,
with no significant signal observed after 1 week. MDA2-Gd
micelles, however, exhibited maximum enhancement after 1
week post-injection. However, like all lipid-based nanopar-
ticles, a fraction of the injection dose was sequestered by
Figure 8 Confocal Microscopy of the Abdominal Arterial Wall o
After Administration of MDA2-Labeled Mn Micelles
Cell nuclei were stained with DAPI (blue, upper left corner), micelles were labeled
macrophages were RPE-labeled anti-CD68 (green, lower left corner). The compos
Figure 9 Representative Correlation Between In Vivo MRI and
The aorta was imaged in vivo prior to and 48 h after the administration of 0.05 m
ing, and the immunohistology was performed. The aorta was opened longitudinally
area of magnetic resonance imaging (MRI) and histological assessment for MDA e
the presence of MDA-lysine epitopes (red).liver, causing bioretention of Mn and Gd (5). Unlike with
targeted Mn micelles, Gd remains in the plaque for at least
a week. Reported studies indicate that intracellular uptake of
Gd may promote cell apoptosis, which may result in
proinflammatory effects (8,30). However, the intracellular
toxicity is strongly dependent upon intracellular uptake into
vesicles (endosomes/lysosomes) and the formation of toxic
insoluble Gd salts. Liver uptake of Mn, however, is not
poE/ Mouse 48 h
hodamine (red, upper left corner), and
ge of all channels is shown in the bottom right corner.
resence of MDA Epitopes
n/kg MDA2-labeled micelles. The mouse was sacrificed immediately after imag-
tained with Sudan (red). The yellow line in the Sudan-stained aorta reflects the
s. Strong MR signal was observed in regions exhibiting plaque deposition andf an a
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proved by the FDA (11).
To avoid potential toxic effects of free Gd, we have also
successfully imaged atherosclerotic lesion in apoE/ mice
with MDA2-, IK17-, and E06-targeted lipid-coated ultra-
small superparamagnetic iron oxide particles (31). Once
aken up by macrophages, iron oxide particles generate MR
ignal loss due to the generation of strong T2/T2* effects.
his approach is qualitatively different than using untar-
eted iron oxide–based nanoparticles that nonspecifically
ccumulate in intraplaque macrophages (32,33). A recent
therapeutic study in patients showed a significant change in
MR signal after 6 to 12 weeks of high-dose atorvastatin
treatment (relative to baseline T2* values), and it is antici-
pated that targeted iron oxide nanoparticles will enable
specific detection and monitoring of high-risk atheroscle-
rotic plaque (31,32).
The clinical relevance of OSE-targeted imaging shown in
the current study was recently demonstrated in coronary
sections from sudden death victims where the presence of
oxidized phospholipids and IK17 epitopes was strongest in
late lesions with macrophage-rich areas, lipid pools, and the
necrotic core, and were most specifically associated with
unstable and ruptured plaque. This was further demon-
strated in living patients with material derived from
carotid, coronary, and renal distal protection devices,
demonstrating the presence of oxidized lipids in clinically
relevant lesions (34).
Study limitations. Although similar imaging efficacy was
observed in 2 atherosclerotic mouse strains, the current
study did not specifically image vulnerable plaques. Ded-
icated toxicology studies will be needed to formally test
the safety of the current targeted manganese nanopar-
ticles. Due to limitations in the current study design, it
was not possible to evaluate the mechanism of uptake of
the targeted micelles in intraplaque macrophages. Future
studies are planned in macrophages scavenger receptor
knockout mice to evaluate the effect of macrophage
phenotype on intracellular uptake. Additionally, the cur-
rent study used extreme in vitro conditions to evaluate
transmetallation. Since other cations, as well as endoge-
nous proteins and macromolecules, may influence trans-
metallation, these studies will be repeated using more
physiological in vivo conditions. Additionally, direct
methods such as ICP– high performance liquid chroma-
tography will be used to evaluate the in vivo concentra-
tion of metabolites that are indicative of transmetallation
(ZnDTPA, CuDTPA, CaDTPA).
Conclusions
The current study demonstrates the use of novel biocom-
patible Mn molecular imaging probes for the in vivo
detection of OSE within atherosclerotic lesions. These
observations support the concept that active targeting of
Mn to OxLDL-rich intraplaque macrophages/foam cellswill allow for sensitive and robust in vivo detection and
monitoring of high-risk atherosclerotic lesions.
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APPENDIX
For an expanded Methods section,
please see the online version of this paper.
